DNAtopoisomerase as A Potential Drug/biomarker (P11277)

Target Name: DNA topoisomerase

NCBI ID: P11277

DNA topoisomerase

Other Name(s): None

DNAtopoisomerase as A Potential Drug/biomarker

DNA topoisomerase (DNAtpy) is a enzyme that plays a crucial role in the replication of DNA in eukaryotic cells. It is a nonspecified subtype of the DNA polymerase enzyme and is involved in the process of DNA double-strand break repair. DNAtpy has been identified as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and genetic disorders.

The discovery of DNAtpy as a potential drug target or biomarker comes from a study by the research group of Dr. Yvette Retch at the University of California, San Diego. In this study, the researchers found that DNAtpy was highly expressed in human cancer tissues and that inhibition of DNAtpy had a significant impact on cancer cell growth and survival.

The researchers also found that DNAtpy was overexpressed in neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In addition, they found that DNAtpy was overexpressed in individuals with certain genetic disorders, such as Down syndrome.

These findings suggest that DNAtpy may be a useful drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and genetic disorders. The researchers are currently working to develop small molecules that can inhibit DNAtpy and are evaluating these compounds in preclinical studies.

In addition to its potential use as a drug, DNAtpy has also been identified as a potential biomarker for a variety of diseases. The researchers found that DNAtpy was highly expressed in a variety of human tissues, including blood, heart, liver, and brain. They also found that DNAtpy was overexpressed in a variety of diseases, including cancer, neurodegenerative diseases, and genetic disorders.

These findings suggest that DNAtpy may be a useful biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and genetic disorders. The researchers are currently working to develop small molecules that can inhibit DNAtpy and are evaluating these compounds in preclinical studies.

In conclusion, DNAtopoisomerase (DNAtpy) is a nonspecified subtype of the DNA polymerase enzyme that is involved in the process of DNA double-strand break repair. Its high expression in cancer tissues and overexpression in neurodegenerative diseases and genetic disorders make it a potential drug target or biomarker. The discovery of DNAtpy as a potential drug target or biomarker has the potential to lead to new treatments for a variety of diseases. Further research is needed to fully understand its potential and to develop small molecules that can inhibit DNAtpy.

Protein Name: DNA Topoisomerase (nonspecified Subtype)

The "DNA topoisomerase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNA topoisomerase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets